Advanced Biomed Inc. SEC filings document a Nevada emerging growth company with common stock listed on Nasdaq under ADVB. The filings identify the issuer’s biotechnology focus in precision medicine and advanced diagnostics and record material events affecting its capital structure, listed security and corporate organization.
Recent 8-K and amended 8-K filings cover securities purchase agreements, an equity line of credit, a short-term loan agreement, share issuances, the 1-for-20 reverse stock split and Nasdaq minimum-bid-price correspondence. They also document director and officer changes, material definitive agreements, completed acquisition or disposition activity, amendments to charter documents, and other formal disclosures tied to governance, financing and shareholder rights.
Advanced Biomed Inc. completed its shift from biomedical operations to enterprise AI financial verification. It acquired Acellent Technologies (Hong Kong) Co. Limited on April 30, 2026, issuing 270,000 common shares valued at $1,080,000, and disposed of its historical biomedical businesses. Its FinTruth platform generated approximately $127,637 in fiscal 2026 revenue.
For the year ended June 30, 2026, continuing operations recorded a $6,261,276 loss, versus a $1,086,470 loss in fiscal 2025. Consolidated net income was $6,677,077, and results included a $14,015,417 gain on disposal of subsidiaries, net of tax.
At June 30, 2026, cash was $385,535, while net amounts due from former subsidiaries were $12,959,826; Advanced Biomed said these receivables meant reported working capital was not cash immediately available for operations. Management concluded internal control over financial reporting was ineffective, citing two material weaknesses involving finance staffing and policies, and approval and user-access controls.
Advanced Biomed Inc. (ADVB) has a Schedule 13G reporting that Advance On Ventures Limited and Chen Yi Lee are passive beneficial owners of its common stock.
Advance On Ventures Limited beneficially owns 109,200 shares of common stock, representing 6.6% of the class, with sole voting and dispositive power over these shares. Chen Yi Lee beneficially owns a total of 123,840 shares, or 7.5% of the common stock, including the 109,200 shares held by Advance On Ventures Limited, over which he has sole voting and dispositive power, plus 14,640 shares held directly. Percentages are based on 1,652,133 shares outstanding as of May 29, 2026.
Advanced Biomed Inc. (ADVB) reported that ten percent owner Pau Hung To recorded two code J “other acquisition or disposition” transactions in its common stock on July 27, 2026. In total, 176,225 shares were transferred to Lu Yi and Zhao Jie in satisfaction of $480,000 of indebtedness.
Advanced Biomed Inc. (ADVB) is the subject of an amended Schedule 13G/A filed by shareholder Pau Hung To. The reporting person now reports 0 shares of Advanced Biomed common stock beneficially owned, representing 0% of the class. This change reflects transfers of 100,000 shares to Lu Yi and 76,225 shares to Zhao Jie on July 27, 2026, in each case in satisfaction of indebtedness of the reporting person with an aggregate principal amount of $480,000. Following these transfers, the filer reports no voting or dispositive power over any Advanced Biomed shares.
Advanced Biomed Inc. (ADVB) reports that investor Pau Hung To, a citizen of the People's Republic of China, has filed a Schedule 13G indicating beneficial ownership of 176,225 shares of common stock. This represents 12.75% of Advanced Biomed's common shares outstanding.
The 176,225 shares reflect an original issuance of 4,405,625 shares to Pau Hung To on October 24, 2022 under a Debt-For-Equity Exchange Agreement dated June 30, 2022, in satisfaction of indebtedness owed by Advanced Biomed. The share amount has been adjusted solely for subsequent stock splits: a 4-for-1 forward split on May 16, 2023, a 1-for-5 reverse split on October 15, 2024, and a 1-for-20 reverse split on February 20, 2026. The reported 12.75% stake is based on 1,382,133 shares outstanding as of March 31, 2026. Pau Hung To reports sole voting and dispositive power over all 176,225 shares.
Advanced Biomed Inc. reports that it is terminating a previously established equity purchase arrangement with Helena Global Investment Opportunities I Ltd. The Purchase Agreement, signed on June 6, 2025, had allowed the company, at its discretion, to issue and sell up to $25,000,000 of common stock with a par value of $0.001 per share.
On July 14, 2026, the company delivered a Termination Notice under a contractual provision permitting termination with five trading days’ prior written notice, provided there were no outstanding Advance Notices and all amounts, including all Commitment Fee Shares, had been paid. These conditions were satisfied, and the company states it has not issued or sold any shares to the investor pursuant to any Advance under the agreement other than the Commitment Fee Shares. The termination becomes effective on July 21, 2026.
Advanced Biomed Inc. reported the results of its annual stockholder meeting held on June 30, 2026, where all five proposals passed. Stockholders elected five directors, approved executive compensation on a non-binding basis, and chose annual advisory votes on pay.
Holders of 1,422,573.80 common shares were represented, about 86.105% of the 1,652,133 shares outstanding and entitled to vote as of May 29, 2026, establishing a quorum. Stockholders also ratified WWC, P.C. as auditor for the fiscal year ending June 30, 2026, and approved a potential adjournment of the meeting if needed.
Advanced Biomed Inc. has entered into a material definitive agreement to sell 100% of the issued and outstanding shares of its wholly owned Taiwan subsidiary, Advanced Biomed Inc. (Taiwan), for an aggregate purchase price of US$490,000. This entity conducts the company’s biomedical research and development operations, including the A+PerfusC integrated perfusion 3D cell culture platform.
The buyer is described as an unrelated third party, and the transaction is expected to close within three months from June 30, 2026, subject to conditions in the share purchase agreement. After this disposition, Advanced Biomed plans to continue operating its remaining businesses, including AI-focused operations through Acellent Technologies (Hong Kong) Co. Limited.